Get informed when a big investor buys or sells
+ Follow96.23
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for TLPPF is 96.23. That is above the Healthcare sector average of 28.76. Investors often review this figure alongside Telix Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, TLPPF currently prints 96.23 for P/E ratio, while the sector average sits near 28.76. That is roughly 234.6% above the sector mean. Large gaps often invite a closer look at Telix Pharmaceuticals Limited's growth, margins, and balance sheet.
A P/E ratio of 96.23 for Telix Pharmaceuticals Limited is not 'good' or 'bad' on its own. Compare it with the peer average (28.76) and with TLPPF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TLPPF's P/E ratio (96.23), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Telix Pharmaceuticals Limited's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.